Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234741 · ClinicalTrials.gov registry record · Phase 2
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
A Phase 2 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00234741: Completed Phase 2 study, sponsored by Synta Pharmaceuticals.
NCT00234741 is a Phase 2 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00234741, a Phase 2 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
STA-5326 is an oral experimental drug that has been shown to block the release of interleukin-12 from peripheral blood mononuclear cells. Given this activity on the immune system, STA-5326 mesylate is a potential treatment for various autoimmune diseases, such as Crohn's disease, that are mediated by the inappropriate expression of Th1 cytokines. This study is evaluating the use of STA-5326 mesylate in patients with moderate to severe, active Crohn's disease. Study visits include a screening visit, 4 treatment period visits over 4 weeks and a follow-up visit that will occur 7 days following the end of treatment. Subjects may continue treatment for an additional 4 weeks of open label STA-5326 mesylate administration that includes an additional 2 treatment period visits. Subjects will undergo a colonoscopy with biopsy collection at baseline, at the end of the 4 week blinded phase and at the end of the 4 week open label phase.
Interventions
- DRUG STA-5326 mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00234741
The ClinicalTrials.gov registry entry for NCT00234741 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STA-5326 mesylate is the first listed.
NCT00234741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00234741 about?
NCT00234741 is a clinical study titled "Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease". STA-5326 is an oral experimental drug that has been shown to block the release of interleukin-12 from peripheral blood mononuclear cells. Given this activity on the immune system, STA-5326 mesylate is a potential treatment for various autoimmune diseases, such as Crohn's disease, that are mediated b...
What is the current status of trial NCT00234741?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2005-11.
What interventions are being tested in trial NCT00234741?
The interventions under investigation include: STA-5326 mesylate (DRUG).
Who is sponsoring clinical trial NCT00234741?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.